We recently showed that oxadiazoles have anti-Trypanosoma cruzi activity at micromolar concentrations. These compounds are easy to synthesize and show a number of clear and interpretable structure-activity relationships (SAR), features that make them attractive to pursue potency enhancement. We present here the structural design, synthesis, and anti-T. cruzi evaluation of new oxadiazoles denoted 5a-h and 6a-h. The design of these compounds was based on a previous model of computational docking of oxadiazoles on the T. cruzi protease cruzain. We tested the ability of these compounds to inhibit catalytic activity of cruzain, but we found no correlation between the enzyme inhibition and the antiparasitic activity of the compounds. However, we found reliable SAR data when we tested these compounds against the whole parasite. While none of these oxadiazoles showed toxicity for mammalian cells, oxadiazoles 6c (fluorine), 6d (chlorine), and 6e (bromine) reduced epimastigote proliferation and were cidal for trypomastigotes of T. cruzi Y strain. Oxadiazoles 6c and 6d have IC 50 of 9.5 ± 2.8 and 3.5 ± 1.8 lM for trypomastigotes, while Benznidazole, which is the currently used drug for Chagas disease treatment, showed an IC 50 of 11.3 ± 2.8 lM. Compounds 6c and 6d impair trypomastigote development and invasion in macrophages, and also induce ultrastructural alterations in trypomastigotes. Finally, compound 6d given orally at 50 mg/kg substantially reduces the parasitemia in T. cruzi-infected BALB/c mice. Our drug design resulted in potency enhancement of oxadiazoles as anti-Chagas disease agents, and culminated with the identification of oxadiazole 6d, a trypanosomicidal compound in an animal model of infection.
Introduction
It is estimated that 10% of the whole Latin America population is suffering from American trypanosomiasis or Chagas disease, caused by the intracellular protozoan Trypanosoma cruzi.
1,2 This situation is alarming because there are no vaccines available and the current treatment, which is only based on benznidazole (Bdz), suffers limitations of efficacy and toxicity. 3, 4 The T. cruzi cysteine-protease cruzain is an important drug target because it is expressed in all stages of the parasite life cycle and play key roles as a virulence factor. [5] [6] [7] [8] An important proof-concept of cruzain as a drug target is that its inhibitors efficiently eradicate parasites in host-cells and substantially reduce parasitemia in different animal models of infection. 9, 10 The current status of cruzain inhibitor research is quite promising because some of these lead compounds are nonpeptidic and quite similar to drug-like compounds, a step that is important for successful drug development. [10] [11] [12] Therefore, the identification or structural optimization of cruzain inhibitors is a promising avenue for Chagas disease chemotherapy.
There is a substantial number of papers reporting oxadiazoles as anti-parasitics. Oxadiazoles are frequently explored as bioisosters of ester and amide functionalities. From this point of view, oxadiazoles are considered potential cysteine protease inhibitors because they are similar to peptide bonds. [13] [14] [15] There mexicana. [16] [17] [18] [19] [20] In light of these findings, we found reasonable to explore oxadiazoles as anti-T. cruzi agents. In 2009, we reported a congener series of N-acylhydrazone 1,2,4-oxadiazoles, denoted 4a-h, exhibiting toxicity for trypomastigotes of T. cruzi Y strain. 21 The oxadiazoles 4a-h showed minimal toxicity for mouse splenocytes and a clear set of structure-activity relationships. A computational model of docking suggested oxadiazoles 4a-h might be cruzain ligands. This model also suggested that the 4-hydroxyphenyl group near to the N-acylhydrazone is probably oriented in a region of cruzain structure which is also the binding site for highly-potent cruzain inhibitors. 12 Based on this binding model, we thought that structural modifications on 4-hydroxyphenyl might lead to potency enhancement (Fig. 1) . The functional activity of oxadiazole 4a-h as trypanosomicidal compounds led us to explore potency enhancement by molecular modification. For this study, we synthesized oxadiazoles 5a-h and 6a-h, composed of the 3-aryl-1,2,4-oxadiazole-5-carbohydrazides of the previously identified anti-T. cruzi oxadiazoles 4a-h with a replacement of 4-hydroxyphenyl group by 4-hydroxy-3-methoxyphenyl for 5a-h and 1,3-benzodioxole for 6a-h. These chemical replacements were selected due to the analogy between these chemical groups (Fig. 1) . [22] [23] [24] Enhancement of anti-T. cruzi activity in parasite cells was indeed achieved for oxadiazoles 6a-h, furthermore these oxadiazoles impaired trypomastigote development and invasion into host-cells, and mice orally treated with oxadiazole 6d had a substantial reduction of parasitemia.
Results and discussion

Chemistry
The synthesis of compounds 5a-h and 6a-h is depicted in Scheme 1 and is based on a method previously described by our group. 25 This starts with 4-substituted aryl amidoximes, which are freshly prepared from commercially available nitriles; then they react with methyloxalyl chloride yielding the 1,2,4-oxadiazolic compounds in good yields. Further conversion of 1,2,4-oxadiazole methylesters into 1,2,4-oxadiazole hydrazides is achieved with quantitative yields by reacting them with hydrazine hydrate at 0°C during 2 h. These hydrazides, which are key intermediates in our research to investigate the pharmacological properties of 1,2,4-oxadiazoles, 26 are of easy synthesis and produces the final compounds, N-acylhydrazones 5a-h and 6a-h. To establish a SAR between our previously studied oxadiazoles (compounds 4a-h) and oxadiazoles 5a-h and 6a-h described here, we used the same substituents in both cases (R = H, CH 3 , F, Cl, Br, OCH 3 , OH, NO 2 ,). The r pHammet values for these substituents range from À0.37 for OH to 0.78 for NO 2 , and therefore the electronic contribution of the para-substituent on the phenyl group varies significantly and allows us to investigate the importance of each substituent. The physical and spectroscopic data for the compounds 5a-h are described here (experimental materials), while the spectral characterization for 6a-h has been previously described.
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N-Acylhydrazones can yield a mixture of Z-and E-isomers, 24 but the 1 H NMR analysis revealed that the E-isomers predominated (>98%). The mild conditions we used for preparing N-acylhydrazones 5a-h and 6a-h (short reaction time and room temperature) explain the predominance of the E-isomer in the crude products. The X-ray analysis of 6f crystal obtained by crystallization from a dimethylformamide solution exclusively produced the E-diastereomer (Fig. 2) , confirming the 1 H NMR data. Quantum chemistry calculations (ab initio) suggested a planar and E-geometry for compounds 6a-h and showed that two stable conformers of this geometry are possible, differing only by 2.74 kcal/mol. 26 The conformer of lowest energy is synperiplanar, with the carbonyl oxygen and the iminic hydrogen syn to each other. The higher stability of this conformer is because of a nonclassical hydrogen bond between C@O and CH@N, like a five-member ring. The antiperiplanar conformer has the carbonyl oxygen and the iminic hydrogen in opposite sides (anti), and therefore an intramolecular interaction is not possible. The conformations we predicted by quantum chemistry and the observed one by Xray are different. The antiperiplanar conformer observed in the crystalline structure can be explained. By X-ray diffraction, the crystal structure of compound 6f presents one molecule of DMF in the asymmetric unit. The position of the DMF molecule allows its oxygen atom to interact with two hydrogen atoms of the NAH from the imine group (CH@N) and the amide group (N-H) and it provides stability for an antiperiplanar conformer.
Pharmacology
Once the compounds had been chemically characterized, we focused on evaluating their biological activity. All compounds were evaluated against T. cruzi. We first assayed the cell viability of mouse splenocytes treated with oxadiazoles 5a-h and 6a-h. Given that the compounds showed no toxicity in this assay, having an LC 50 higher than 100 lg/mL, they were evaluated against epimastigotes (axenic culture) and bloodstream trypomastigotes of Y strain T. cruzi, using benznidazole (Bdz) as a control drug. The compounds that showed IC 50 values comparable to Bdz were further selected for in vitro and in vivo assays. The ability of these compounds to inhibit the activity of cruzain was also performed in parallel to the parasite cell assays. All compounds were initially tested at 100 lM. For active compounds, a dose-response curve was determined and the IC 50 calculated. Table 1 summarizes the cruzain and anti-T. cruzi activities for oxadiazoles 5a-h and 6a-h.
None of the oxadiazoles 5a-h showed anti-T. cruzi activity. This was an unexpected finding because compounds 5a-h only differ from our early examined oxadiazoles (4a-h) 21 by the introduction of a 3-methoxy group. But we found potent trypanosomicidal activities for oxadiazoles 6a-h. We first noted that the halogenated oxadiazoles 6c, 6d, and 6e were able to inhibit T. cruzi, with IC 50 values quite similar to Bdz (Table 1) . For example, oxadiazoles 6c (fluorine) and 6d (chlorine) have IC 50 of 9.5 ± 2.8 and 3.5 ± 1.8 lM for Y strain trypomastigotes, quite similar to Benznidazole (IC 50 of 11.3 ± 2.8 lM) respectively. Neither oxadiazoles 6c, 6d, and 6e nor benznidazole affected the cell viability of mouse splenocytes up to 100 lg/mL, while these compounds clearly affect parasite proliferation (epimastigotes) and motility (trypomastigotes). The absence of toxicity for mouse splenocytes shows that the cell effects of oxadiazoles and Bdz are specific for T. cruzi. After confirming that the oxadiazoles were able to kill T. cruzi parasites, our next step was to understand how these compounds affect the infection of host cells by trypomastigotes. 27, 28 We tested oxadiazoles 6c, 6d, and 6e in an in vitro model of parasite infection in macrophages. Macrophages were infected with Y strain trypomastigotes and then treated with compounds at 10 lg/mL, including Bdz. Cells were analyzed by light microscopy and the percentage of infected macrophages and the number of amastigotes were determined and compared to untreated infected cells (negative control) and cells treated with benznidazole (positive control).
In untreated-infected macrophages (negative control), the percentage of infected cells is high (Figs. 3 and S1, Supplementary data). As a result, trypomastigotes complete the intracellular cycle into amastigotes, resulting in an average of almost 800 amastigotes per 100 host-cells (Fig. 3) . 29 When 10 lg/mL of oxadiazoles 6c and 6d are added, the percentage of infected macrophages is significantly reduced when compared to untreated cells. Oxadiazole 6e, a bromine analog that was cidal for trypomastigotes (Table 1) , had no activity in these assays. When 10 lg/mL of oxadiazoles 6c or 6d
are added at the moment of infection, the number of infected cells is lower than untreated-infected macrophages ( Fig. S2 Supplementary data). This suggests that oxadiazoles 6c and 6d impair trypomastigote invasion into host-cells. The oxadiazoles 6c and 6d arrested trypomastigote development and invasion of macrophages. Therefore, potency enhancement of anti-T. cruzi activity was achieved for oxadiazoles 6a-h when compared to our previously studied oxadiazoles 4a-h.
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We also investigated the ability of these compounds to inhibit the recombinant cysteine protease of T. cruzi, cruzain. 18 As seen in Table 1 , oxadiazoles 5d, 5e and 6e showed high-affinity for cruzain (IC 50 from 40 to 200 nM). Cruzain inhibition by these three oxadiazoles was higher when they were pre-incubated with the enzyme, consistent with a covalent-mechanism of inhibition. NAcylhydrazones such as compounds 5d and 5e may undergo Michael-addition reactions, yielding covalent adducts with cruzain. 30 Other oxadiazoles of the series 5a-h and 6a-h did not show significant cruzain inhibition at 100 lM, so no SAR could be drawn. The cruzain inhibition observed for oxadiazoles 5d, 5e and 6e was not due to nonspecific binding. The assay was repeated in the absence and the presence of 0.1% Triton X-100. 18 The level of cruzain inhibition did not vary among these conditions, suggesting that enzyme inhibition is not due to compound aggregation. Since there is no reliable correlation between cruzain inhibition and trypanosomicidal properties, the trypanosomicidal effects of oxadiazoles are only in part due to cruzain inhibition, other targets and biochemical pathways must be involved.
To further investigate the mechanism of action of oxadiazoles 6c and 6d, ultrastructural alterations in bloodstream trypomastigotes were analyzed. Electron micrographs are shown in Figure 4 . In comparison to untreated parasites, trypomastigotes incubated with 6c and 6d had membrane protrusions in about 80% of cells. Oxadiazoles 6c and 6d caused mitochondria degeneration, Golgi apparatus and endoplasmic reticulum disorganization, followed by kinetoplast enlargement. When infected macrophages were treated with 3.5 lM of oxadiazole 6d, we could observe that oxadiazole 6d targets mitochondria, causing fragmentation as well as the formation of atypical vacuoles which contain mitochondrial components (Fig. 5) . High-affinity cruzain inhibitors, such as peptide K777, are believed to induce structural alterations in Golgi apparatus, endoplasmic reticulum, and to alter protein trafficking into lysosomes/reservosomes. 31 Alterations of mitochondria and kinetoplast are not observed for well-known cruzain inhibitors. 31, 32 These information differed from those observed here for oxadiazoles 6c and 6d. What we observed is that oxadiazoles substantially alter the mitochondrial morphology, therefore proteins involved in parasite metabolism and bioenergetics might be the molecular targets for oxadiazoles. Instead of attempting to identify these target proteins, we decided to evaluate whether these compounds reduce blood parasitemia in T. cruzi-infected mice.
To determine the maximum tolerated dose (MTD), single oral treatment of oxadiazole 6d to uninfected BALB/c mice (n = 3/ group) at doses of 25, 50, and 100 mg/kg was performed. Mice treated with 6d appeared normal and no mortality was observed. We also measured serum biochemical components in uninfected mice treated with 6d (Table S1 ). In comparison to untreated and uninfected mice, treatment with 6d did not systematically change serum components, suggesting the toxicity of these oxadiazoles is not a major concern. Based on this, oxadiazoles 6c and 6d were administrated at dose of 50 mg/kg to infected mice.
BALB/c mice were infected with Y strain trypomastigotes 33 and treated or not with 6c, 6d, and Bdz. In untreated, infected mice, blood parasitemia was observed after day 8 of parasite inoculation and peaked on day 10 (Fig. 6 ). Benznidazole (Bdz) given orally at 100 mg/kg once a day for 5 days (starting from day 5 after infection) almost eradicated blood parasitemia. Compound 6d substantially reduced blood parasitemia (p <0.001) compared to untreated infected mice. Compound 6c did not reduce parasitemia as much as compound 6d, as expected based on its lower potency. Compound 6e was not tested due to low solubility. N-Acylhydrazones are known for their in vitro trypanosomicidal and cruzain inhibition effects. [34] [35] [36] [37] However, very few N-acylhydrazones that are effective in reducing in vivo infection have been identified. 38 One method for increasing the efficacy of anti-T. cruzi N-acylhydrazones is through the combination with oxadiazole chemistry. [19] [20] [21] From our past studies, we discovered that N-acylhydrazones derived from 1,2,4-oxadiazole chemistry were less potent trypanosomicidal agents than benznidazole, but at least they were more selective for parasite than to mammalian cells. 21 Here, our main aim was to improve the cidal potency by molecular modification. We knew from past SAR model that the N-acylhydrazone motif is more suitable and tolerates molecular modification. In view of this, we planned compounds 5a-h and 6a-h. This structural design was successful and led us to identify the anti-T. cruzi oxadiazole denoted 6d.
We believe that compound 6d merits further chemical optimization because: (a) it has a selectivity window of at least 50 (host cell which were determined based on at least 9 compound concentrations in duplicate. b Determined after 24 h of incubation of trypomastigotes with the compounds. Values were calculated from five concentrations using data obtained from at least two independent experiments (SD given in parenthesis). c Determined after 5 days of incubation of epimastigotes with the compounds. IC 50 was calculated from five concentrations using data obtained from at least two independent experiments (SD given in parenthesis). d Toxicity for splenocytes of BALB/c mouse after 24 h of incubation in the presence of the compounds. e Bdz = Benznidazole; GV = Gentian Violet. Nd., not determined, due to the lack of activity in the tested concentration. SD = standard deviation.
toxicity LC 50 /T. cruzi IC 50 ); (b) it is efficient and well-tolerated in oral treatment; (c) at a dose of 50 mg/kg (140 lmol/kg) parasitemia was reduced in vivo; (d) 6d is a low-molecular weight, achiral, and nonpeptidic compound. These functional properties and chemical features are desirable for a Chagas disease drug candidate. 39 
Conclusions
From our past studies, oxadiazoles were less potent cidals than benznidazole, but they were more selective for parasite versus mammalian cells. Here, our effort was to improve their cidal potency by molecular modification of substituents. To this end, trypanosomicidal properties as well cruzain inhibition of 3-aryl-1,2,4-oxadiazole-5-carbohydrazides containing a 4-hydroxy-3-methoxyphenyl 5a-h or 1,3-benzodioxole 6a-h were determined. Oxadiazole 6d, which features a 1,3-benzodioxole group near to the N-acylhydrazone was identified as the most potent and selective trypanosomicidal compound among them, and endowed with efficacy in reducing blood parasitemia in a mouse model of acute infection. The efficacy observed for oxadiazole 6d in in vitro and in vivo models of infection argues favorably for oxadiazoles as antiparasitic agents and therefore the synthetic redesign of variant forms of oxadiazole 6d is worthy.
Experimental section
Chemistry
Melting points were determined on a Gallenkamp capillary apparatus and are uncorrected. Infrared spectra were determined using KBr discs on a Perkin-Elmer Paragon 500 FT-IR spectrometer. 1 H NMR spectra were determined on a Bruker DPX-200 spectrometer, with chemical shifts d reported in ppm unities relative to the internal standard TMS, using DMSO-d 6 as solvent. Mass spectral were determined by using a Finnigan mass spectrometers model MAT 8200 for low resolution mass spectrometry (MS) and the MAT 95 for high resolution mass spectrometry (HRMS). Values for HRMS lie within the permitted limit intervals with resolution of 10,000. The reactions were monitored by thin layer chromatography (TLC), performed on plates prepared with a 0.2 mm thick silica gel 60 (PF-254 with gypsum, Merck). The developed chromatograms were visualized under ultraviolet light at 254-265 nm. For column chromatography, silica gel 60 (230-400 mesh, Merck) was used. All common laboratory chemicals were purchased from commercial sources and used without previous purification. Crystallographic data for compound 6f can be obtained free of charge at the Cambridge Crystallographic Data Centre (CCDC, deposit number 870707, www.ccdc.cam.ac.uk/data_re-quest/cif).
General procedure for preparation of compounds 5a-h
To a stirred suspension of 0.01 mol of appropriate hydrazide in 5 mL of ethanol, 3-4 drops of concentrated sulfuric acid were added, changing the mixture to a clear solution. Then, vanillin (0.01 mol) previously dissolved in 5 mL of ethanol was added to the mixture at room temperature. After few seconds, a colored solid precipitated and the mixture was stirred for 10 min before the addition of 10 mL of water. After vacuum filtration, the solid was washed with cold water/ethanol 1:1 and then with cold water. Recrystallization from dioxane/water mixture afforded the crystalline solids. Yields, melting points, spectroscopic and spectrometric data are listed below for each compound. 
Animals
Female BALB/c mice (6-8 weeks old) were supplied by the animal breeding facility at Centro de Pesquisas Gonçalo Moniz (Fundação Oswaldo Cruz, Bahia, Brazil) and maintained in sterilized cages under a controlled environment, receiving a balanced diet for rodents and water ad libitum. All experiments were carried out in accordance with the recommendations of Ethical Issues Guidelines, and were approved by the local Animal Ethics Committee. 
Parasites
Epimastigotes of T. cruzi (Y strain) were maintained at 26°C in LIT medium (Liver Infusion Tryptose) supplemented with 10% fetal bovine serum (FBS) (Cultilab, Campinas, SP, Brazil), 1% hemin (Sigma Co, St. Louis, MO, USA), 1% R9 medium (Sigma Co), and 50 lg/ mL gentamycin (Novafarma, Anápolis, GO, Brazil). Bloodstream trypomastigotes forms of T. cruzi were obtained from supernatants of LLC-MK 2 cells previously infected and maintained in RPMI-1640 medium (Sigma Co.) supplemented with 10% FBS, and 50 lg/mL gentamycin at 37°C and 5% CO 2 .
Cruzain inhibition
Cruzain activity was measured by monitoring the cleavage of the fluorogenic substrate Z-Phe-Arg-aminomethylcoumarin (Z-FR-AMC), as previously described. 18 All assays were performed in 96-well plate format, in a final volume of 200 lL, in sodium acetate 0.1 M (pH 5.5), in the presence of 5 mM dithiothreitol (DTT) and 0.01% Triton X-100, except for evaluation of detergent-sensitivity, when inhibition was also evaluated in 0% and 0.1% Triton for comparison. The enzyme was present at the final concentration of 0.4 nM and the substrate at 2.5 lM (K m = 2 lM). All assays were performed in duplicate and followed for 5 min, and cruzain activity was calculated based on initial rates of substrate cleavage compared to a DMSO control. All compounds were dissolved in DMSO.
The initial screen was performed at 100 lM of each compound.
Compounds were first evaluated for time-dependence by comparing percentages of enzyme inhibition by a compound with or without pre-incubation with enzyme for 10 min. During the preincubation step, cruzain and compound concentrations were 10-fold higher than in the final assay. Since compounds were observed to be time-dependent, consistently with a covalent mode of inhibition, all subsequent assays were performed with a 10 min preincubation. Compounds which inhibited over 50% of cruzain activity at 100 lM had their IC 50 determined and were further evaluated for detergent-sensitivity. Dose-response curves were determined based on at least nine compounds concentrations, varying from 100 lM to 0.1 nM in fourfold dilutions. Data was analyzed with Prism 4 (GraphPad) employing non-linear regression.
Cytotoxicity to mouse splenocytes
Splenocytes obtained from BALB/c mice were placed into 96-well plates at a cell density of 5 Â 10 6 cells/well in RPMI-1640 medium supplemented with 10% of FBS and 50 lg mL À1 of gentamycin. Each test inhibitor was used in five concentrations (1. 23, 3.70, 11.11, 33.33 , and 100 lg mL À1 ) in triplicate. To each well, an aliquot of test inhibitor suspended in DMSO was added. Controls included wells only containing either solvent (untreated cells) or gentian violet (positive control). The plate was incubated for 24 h at 37°C and 5% CO 2 . After incubation, 1.0 lCi of 3 H-thymidine (Perkin Elmer, Waltham, USA) was added to each well, and the plate was returned to the incubator. The plate was then transferred to a beta-radiation counter (Multilabel Reader, Finland), and the percent of 3 H-thymidine was determined. Cell viability was measured as the percent of 3 H-thymidine incorporation for treated-cells in comparison to untreated cells. LD 50 values were calculated using data-points gathered from two independent experiments.
Antiproliferative activity for epimastigotes
Epimastigotes were counted in a hemocytometer and then dispensed into 96-well plates at a cell density of 10 6 cells/well. Test inhibitors, dissolved in DMSO, were diluted into five different concentrations (1. 23, 3.70, 11.11, 33.33 , and 100 lg/mL) and added to the respective wells in triplicate. The plate was incubated for 5 days at 26°C, and aliquots of each well were collected and the number of viable parasites were counted in a Neubauer chamber, and compared to untreated parasite culture. IC 50 calculation was carried out using non-linear regression on Prism 4.0 GraphPad software. This experiment was done in triplicate, and benznidazole (LAFEPE, Pernambuco, Brazil) was used as the reference inhibitor.
Cytotoxicity for trypomastigotes
Trypomastigotes collected from the supernatants of LLC-MK 2 cells were dispensed into 96-well plates at a cell density of 4 Â 10 5 cells/well. Test inhibitors, dissolved in DMSO, were diluted into five different concentrations and added into their respective wells, and the plate was incubated for 24 h at 37°C and 5% of CO 2 . Aliquots of each well were collected and the number of viable parasites, based on parasite motility, was assessed in a Neubauer chamber. The percentage of inhibition was calculated in relation to untreated cultures. IC 50 calculation was also carried out using a non-linear regression with Prism 4.0 GraphPad software. This experiment was repeated once, and benznidazole was used as the positive control.
Trypomastigote development
Peritoneal exudate macrophages were seeded at a cell density of 2 Â 10 5 cells/well in a 24 well-plate with rounded coverslips on the bottom in RPMI supplemented with 10% FBS and incubated for 24 h. Cells were then infected with trypomastigotes at a ratio of 10 parasites per macrophage for 2 h. Free trypomastigotes were removed by successive washes using saline solution. Each test inhibitor was dissolved in DMSO at 10 lg/mL and incubated for 6 h. The medium was replaced by a fresh medium and the plate was incubated for 4 days. Cells were fixed in methanol and the percentage of infected macrophages and the mean number of amastigotes/infected macrophages was determined by manual counting after Giemsa staining in an optical microscope (Olympus, Tokyo, Japan). The percentage of infected macrophages and the number of amastigotes per macrophage was determined by counting 100 cells per slide.
Trypomastigote invasion
Peritoneal macrophages (10 5 cells) were plated onto 13-mm glass coverslips in 24-well plate and kept for 24 h. The plate was washed with saline solution and then trypomastigotes were added at a cell density of 1.25 Â 10 7 along with the addition of test inhibitor (stock solution at 10 lg/mL). The plate was incubated for 2 h at 37°C and 5% CO 2 , followed by five washes with saline solution to remove extracellular trypomastigotes. Plates were maintained in RPMI medium supplemented with 10% FBS at 37°C for 2 h. Infected cells were examined for the presence of amastigotes by optical microscopy using a standard Giemsa staining.
Ultrastructural studies
Trypomastigotes at a cell density of 3 Â 10 7 were treated with test inhibitors 6c (9.5 lM) and 6d (3.5 lM) for 24 h. Parasites were then fixed with 2% formaldehyde and 2.5% glutaraldehyde (Electron Microscopy Sciences, PA, USA) in sodium cacodylate buffer (0.1 M, pH 7.2) for 1 h at room temperature. After fixation, parasites were washed three times with sodium cacodylate buffer (0.1 M, pH 7.2), and post-fixed with a 1.0% solution of osmium tetroxide (Sigma Chemical Co., MO, USA) for 1 h. Cells were subsequently dehydrated in increasing concentrations of acetone (30%, 50%, 70%, 90% and 100%) for 10 min at each step and embedded in resin Polybed (PolyScience family, Warrington, PA, USA). Ultrathin sections were prepared on an ultramicrotome Leica UC7 and sections were collected on copper grids of 300 meshes, contrasted with uranyl acetate and lead citrate and observed under a JEOL TEM-1230 transmission electron microscope. For scanning electron microscopy, trypomastigotes treated with 6c (30 lM) or 6d (10 lM) and fixed in the same conditions were washed in 0.1 M cacodylate buffer, and allowed to adhere in coverslips pre-coated with poly-L-lysine (Sigma Co.). After adherence, cells were post-fixed with a solution of osmium tetroxide containing 0.8-1% of potassium ferrocyanide for 30 min. Cells were subsequently dehydrated in the presence of increasing concentrations of ethanol (30%, 50%, 70%, 90%, and 100%) during 15 min each step, and then subjected to the critical point, metallized with gold and analyzed in a JEOL JSM-6390LV scanning electron microscope. The same procedure was performed for TEM in infected macrophages treated with compound 6d.
Toxicity in mice
Female BALB/c mice (6-8 weeks old; n = 3/group) were orally treated with oxadiazole 6d at doses of 100, 50 and 25 mg/kg. Animals were monitored for signs of general toxicity, including behavior and feeding, until 24 h after treatment. Heparinized blood samples were collected after 24 h of treatment, centrifuged for 3 min. to separate out from cells and then serum components were analyzed using Analyst Ò (Hemagen, Columbia, USA) platform system.
Infection in mice
Female BALB/c mice (6-8 weeks old) were infected with bloodstream trypomastigotes by intraperitoneal inoculation of 10 4 parasites in 100 lL of saline solution and then mice were divided in groups (six animals per group). After the day 5 of infection, treatment with 50 mg/kg weight of drugs 6c and 6d was given orally for five consecutive days. For the control group, Benznidazole was given orally at dose of 100 mg/kg weight. Animal infection was monitored daily by counting the number of motile parasites in 5 lL of fresh blood sample drawn from the lateral tail veins as recommended by standard protocols. 33 
Statistical analyses
To determine the statistical significance of each group in the in vitro/in vivo experiments, the one-way ANOVA test and the Bonferroni for multiple comparisons were used. A p value <0.05 was considered of statistical significance. The data are representative of at least two or three experiments ran in triplicate.
